Leap therapeutics to present new data from part a of the defiance study of dkn-01 plus bevacizumab and chemotherapy in colorectal cancer patients at the 2024 asco gastrointestinal cancers symposium

Cambridge, mass. , dec. 11, 2023 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the company will be presenting new data in second-line patients with advanced colorectal cancer from the defiance study, a phase 2 study evaluating dkn-01, leap's anti-dickkopf-1 (dkk1) antibody, in combination with standard of care bevacizumab and chemotherapy at the upcoming 2024 american society of clinical oncology (asco) gastrointestinal cancers symposium taking place in san francisco, ca and virtually on january 18-20, 2024.
LPTX Ratings Summary
LPTX Quant Ranking